-
Mashup Score: 1Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D - MedCity News - 28 day(s) ago
Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
Most antibody drugs block signaling. Diagonal Therapeutics pairs computational and experimental techniques to design antibodies that spark signaling. https://t.co/2ray0tndb5 #drugdiscovery #startups #AI #cardiovasculardisease #MCNManual https://t.co/8dLm8VM1Cn